Phosphate binding therapy in dialysis patients: Focus on lanthanum carbonate

Therapeutics and Clinical Risk Management

Volumn 4, Issue 5, 2008, Pages 887-893

  Mohammed, Ismail A ^a   Hutchison, Alastair J ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Dialysis; Hyperphosphatemia; Lanthanum carbonate; Phosphate binding

Indexed keywords

ALUMINUM; ALUMINUM SALT; CALCIUM ACETATE; CALCIUM CARBONATE; CALCIUM PHOSPHATE; LANTHANUM CARBONATE; MAGNESIUM; MAGNESIUM IRON HYDROXYCARBONATE; MAGNESIUM SALT; PHOSPHATE; PHOSPHATE BINDING AGENT; PLACEBO; SEVELAMER; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

ABDOMINAL PAIN; ANEMIA; ARTERY CALCIFICATION; BLOOD VESSEL CALCIFICATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DIET RESTRICTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG SAFETY; DRUG TOLERABILITY; DYSERYTHROPOIESIS; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; LIVER TOXICITY; MAXIMUM TOLERATED DOSE; METABOLIC ACIDOSIS; MONOTHERAPY; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; OPTIMAL DRUG DOSE; OSTEOMALACIA; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; RENAL OSTEODYSTROPHY; REVIEW; SIDE EFFECT; SOFT TISSUE CALCIFICATION; VOMITING;

EID: 56749136194     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Al-Baaj F, Speake M, Hutchison AJ. 2005. Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study. Nephrol Dial Transplant, 20:775-82.
2. Bleyer AJ, Burke SK, Dilton M, et al. 1999. A comparison of a calcium free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphataemia in haemodialysis patients. Am J Kidney Dis, 33:694-701.
3. Block GA, Klassen PS, Lazarus JM, et al. 2004. Mineral metabolism, mortality and morbidity in maintenance haemodialysis. J Am Soc Nephrol, 15:2208-18.
4. Block GA, Port FK. 2000. Re-evaluation of risks associated with hyperphosphataemia and hyperparathyroidism in dialysis patients: recommendation for change in management. Am J Kidney Dis, 35:1226-37.
5. Chertow GM, Burke SK, Raggi P. Treat to Goal Working Group. 2002. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int, 62:245-52.
6. Damment SJ, De Broe ME, D'Haese PC, et al. 2007. Incredulous effects of lanthanum? Toxicol Lett, 168:186-9.
7. Damment SJ, Pennick M. 2007. Systemic lanthanum is excreted in the bile of rats. Toxicol Lett, 171:69-77.
8. Delmez J, Slatopolsky E. 1992. Hyperphosphatemia, its consequence and treatment in patients with chronic renal failure. Am J Kidney Dis, 4:313-7.
9. Delmez JA, Slatopolsky E, Martin KJ, et al. 1982. Mineral, vitamin D and parathyroid hormone in continuous ambulatory peritoneal dialysis. Kidney Int, 21:862-7.
10. D'Haese PC, Spasovski GB, Sikole A, et al. 2003. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl, 85:S73-8.
11. Finn WF, Joy MS, Haldick GA. 2004. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol, 62:193-201.
12. Finn WF. SPD 405-307 Lanthanum Study Group. 2006. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol, 65:191-202.
13. Gonzalez-Revalderia J, Casares M, de Paula M, et al. 2000. Biochemical and haematological changes in low-level aluminium intoxication. Clin Chem Lab Med, 38:221-5.
14. Goodman WG, Goldin J, Kuizon BD, et al. 2000. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med, 342:1478-83.
15. Goodman WG. 2001. Vascular calcification in chronic renal failure. Lancet, 358:1115-6.
16. Hutchison AJ, Al-Baaj F. 2005. Lanthanum carbonate for the treatment of hyperphosphatemia in renal failure and dialysis patients. Expert Opin Pharmacother, 6:319-28.
17. Hutchison AJ, Barnett ME, Krause R, et al. on behalf of the SPD405-309 Lanthanum Study Group. 2008. Long-term efficacy and safety profile of lanthanum carbonate: Results for up to 6 years of treatment. Nephron Clin Pract. In press.
18. Hutchison AJ, Laville M. on behalf of the SPD405-313 Lanthanum Study Group. 2008. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. Nephrol Dial Transplant, Jun 24.
19. Hutchison AJ, Maes B, Vanwalleghem J, et al. 2005. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract, 100:c8-c19.
20. Hutchison AJ, Maes B, Vanwalleghem J, et al. 2006. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin Pract, 102:c61-71.
21. Hutchison AJ, Speake M, Albaaj F. 2004. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4 week, dose finding, open-label study with lanthanum carbonate. Nephrol Dial Transplant, 19:1902-6.
22. Hutchison AJ. 2004. Improving phosphate binder therapy as a way forward. Nephrol Dial Transplant, 19:i19-i24.
23. Joy MS, Finn WF. 2003. Randomized, double-blind, placebo-controlled, dose titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate. a new phosphate for the treatment of hyperphosphataemia. Am J Kidney Dis, 42:96-107.
24. Knoll O, Kellinghaus H, Betram HP, et al. 1984. Gastrointestinal absorption of aluminium in chronic renal insufficiency. Contrib Nephrol, 38:24-31.
25. Kopple JD, Coburn JW. 1973. Metabolic studies of low protein diet in uraemia: 11.Calcium, phosphorous, and magnesium. Medicine, 52:597-607.
26. Lamb EJ, Hodsman A, van Schalkwyk D, et al. 2007. Serum calcium, phosphate, parathyroid hormone, albumin, aluminium and cholesterol achievement on replacement therapy (Chapter 9). Nephrol Dial Transplant, 22(Suppl 7):105-18.
27. Lowrie EG, Lew NL. 1990. Death risk in haemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis, 15:458-82.
28. Lowrie GE, New NL. 1990. Death risk in haemodialysis patients: the predictive value of commonly measured variables and evaluation of death rate differences between facilities. Am J Kidney Dis, 15:458-82.
29. Mai M, Emmett M, Sheikh M, et al. 1989. Calcium acetate an effective phosphate binder in patients with renal failure. Kidney Int, 36:690-5.
30. Malluche HH. 2002. Aluminium and bone disease in chronic renal failure. Nephrol Dial Transplant, 17(Suppl 2):21-4.
31. McIntyre CW. 2007. New developments in the management of hyperphosphatemia in chronic kidney disease. Semin Dial, 20:337-41.
32. Pennick M, Dennis K, Damment SJ. 2006. Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate. J Clin Pharmacol, 46:738-46.
33. Qunibi WY, Hootkins RE, McDowell LL, et al. 2004. Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int, 65:1914-26.
34. Schaefer K, Umlauf E, von Herrath D. 1992. Reduced risk of hypercalcemia for hemodialysis patients by administering calcitriol at night. Am J Kidney Dis, 19:460-4.
35. Wills MR, Savory J. 1983. Aluminium poisoning: dialysis encephalopathy, osteomalacia and anaemia. Lancet, 2:29-34.